ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,583.50
-6.50 (-0.41%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.50 -0.41% 1,583.50 1,582.50 1,583.00 1,595.50 1,580.00 1,593.00 5,931,081 16:35:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.22 65.15B

ADRs End Higher; National Bank of Greece Rises

22/06/2015 11:35pm

Dow Jones News


Gsk (LSE:GSK)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Gsk Charts.

International stocks trading in New York closed higher on Monday.

The BNY Mellon index of American depositary receipts rose 1.8% to 148.42. The European index increased 2% to 147.26, the Asian index improved 1.5% to 154.95, the Latin American index rose 1.1% to 219.68 and the emerging markets index increased 1.2% to 264.60.

National Bank of Greece was among the companies with ADRs that traded actively.

News out of Greece lifted stocks around the globe. The Wall Street Journal reported that the Greek government's latest plan makes a potentially major concession on cutting deficits in its pension system. The plan was formally submitted to creditors Monday and could be a big step toward ending a monthslong deadlock that has spurred talk of a potential Greek exit from the eurozone. Still, eurozone leaders cautioned that an immediate breakthrough was unlikely. ADRs of National Bank of Greece SA (NBG, ETE.AT) rose 18% to $1.30.

ADRs of Eni SpA (E, ENI.MI) rose 5.1% to $38.14 after Deutsche Bank stated in a note to clients that the Italy-based energy giant shouldn't rush the sale of its 43% stake in troubled oil services company Saipem. The bank said that while the sale would raise much-need cash for Eni and would allow the oil-and-gas company to deconsolidate 4.5 billion euros ($ billion) of Saipem's debt, the past few years have been rough for the unit whose shares having lost half their value in the past 12 months. "The equity market is materially undervaluing Saipem," the bank said.

Fly Leasing Ltd. (FLY) said it can do $2 billion in commercial-jet deals the next two years after agreeing to sell 1/4 of its older fleet to an unnamed buyer for $985 million. The company is considering sale/leaseback transactions, taking over an airline's orders and renting the planes back to it, an increasingly crowded and competitive space but one expected to account for 20% of plane deliveries this year. New entrants also are expected, with at least one large U.S. bank looking to enter an aircraft-finance market largely vacated by American lending banks a year ago. ADRs rose 1.7% to $15.85.

GlaxoSmithKline PLC (GSK, GSK.LN) said it is selling meningitis vaccines Nimenrix and Mencevax to Pfizer Inc.'s (PFE) Irish subsidiary for 115 million euros ($130.6 million), aiming to gain regulatory approval for a deal with Novartis AG (NVS, NOVN.VX) that includes Glaxo buying Novartis's vaccines business. GlaxoSmithKline ADRs rose 39 cents to $43.45 and Novartis ADRs increased 1.9% to $102.12.

ADRs of Orange SA (ORAN, ORA.FR) rose 7.3% to $16.70 after European telecom company Altice SA said it has made an offer to buy France's Bouygues Telecom, confirming weekend reports of a multibillion-dollar takeover approach which could create France's largest operator by subscribers. A merger between the two companies would create France's largest mobile telephone operator, ahead of Orange SA, the country's former monopoly.

ADRs of STMicroelectronics NV (STM, STM.FR, STM.MI) rose 3.9% to $8.30 after Barclays upgraded the chip maker to equal weight and raised the price target. "We believe estimates have reached a bottom and a new cost-cutting plan could lift expectations from depressed levels. Most of [STMicro's] businesses are now healthy," Barclays said. What's still struggling is digital products "after a number of unconvincing turnaround plans."

Write to Tess Stynes at tess.stynes@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock